Health Biotech Limited
Sector 34, Chandigarh
SEND SMS
SEND EMAIL
Product Details:
| Type | Allopathic |
| Form of Medicine | Injection |
| Medicine Type | Allopathic |
| Usage | Commercial |
| Composition : | Each vial contains Vinblastin Sulphate USP 1.0mg |
| Indications : | Vinblastine sulfate (vinblastine sulfate injection) is indicated in the treatment of the following: - Frequently Responsive Malignancies - Generalized Hodgkin's disease - Lymphocytic lymphoma (nodular and diffuse, poorly and well differentiated) - Histiocytic lymphoma - Mycosis fungoides (advanced stages) - Advanced carcinoma of the testis - Kaposi's sarcoma - Letterer-Siwe disease - Less Frequently Responsive Malignancies - Choriocarcinoma resistant to other chemotherapeutic agents - Carcinoma of the breast, unresponsive to appropriate endocrine surgery and hormonal therap |
| Contraindications : | Pregnancy. Granulocytopenia, Bacterial infections. |
| Adverse Effects : | Hair loss, leucopenia, neuritic pain, constipation, sensory loss, paresthesias, difficulty in walking (stepping gait), loss of deep tendon reflexes, muscle wasting, fever, hypersensitivity reaction, polyuria, urinary retention, hypertension, hypotension, cranial nerve palsy, headache, bone pains, jaw pain, parotid pain, myalgia, convulsions, syndrome of inappropriate secretion of ADH.. |
| Dosage : | Given I.V. at weekly intervals. Children : 2mg/m2 (if <10kg, start with 0.005 mg/kg/week) adult : 1.4mg/m2. Decrease the dose to 50%, if S. bilirubin is >3mg/dl. Not given to patients getting radiation therapy through ports that includes liver. |
| Precautions: | Toxicity may be enhanced in the presence of hepatic insufficiency. - Acute uric acid nephropathy, - Acute shortness of breath severe broncospasm have been reported following the administration of vinca alkaloids. |
Product Details:
| Product Type | Finished Product |
| Medicine Type | Allopathic |
| Usage/Application | Commercial |
| Composition : | 500mg 250mg, 1gm 0.5gm |
| Indications : | LRTI, GIT infections. |
| Dosage : | Adult : Mild to moderate : 1g/0.5g to 2g/1g of cefotaxime/sulbactam every 8-12 hours. Moderate to severe : 1g/0.5g to 2g/1g of cefotaxime/sulbactam every 6-8 hours. Children : 100/50 to 150/75 mg of cefotaxime/sulbactam per kg b.w. per day in three divided doses. |
Product Details:
| Type of Medicines | Allopathic |
| Dosage Form | Injection |
| Grade standard | Medicine Grade |
| Composition : | 400mg/2ml,1000mg/5ml |
| Indications : | As a mucolytic in respiratory disorder associated with the production of viscous mucus such as acute and chronic bronchitis. In alveolar protenosis to remove proteinaceous material by repeated lavage with heparin and acetylcysteine which may prolong survival up to 5 years. |
| Dosage : | Nebulisation : (Face mask, mouth piece, tracheostomy) 3-5ml of a 20% solution 3-4 times daily. Orally : 200mg three times daily. Children up to 2 years may be given 200mg once daily and those between 2-6 years 200mg twice daily. |
Product Details:
| Type | Allopathic |
| Form of Medicine | Injection |
| Usage | Commercial |
| Composition | 1mg/ml,2mg/2ml |
| Indications | Acute leukemia, lymphomas, Hodgkin's disease, non-Hodgkin lymphosarcoma, neuroblastoma, rhabdomyosarcoma, Wilm's tumour. |
| Contraindications | Pregnancy, lactation, demyelinating form of Charcot Marie tooth disease. |
| Safety Profile | The needle should be properly placed in the vein. If leakage occurs in surrounding tissues, considerable irritation will occur. Local injection of & moderate heat will minimize the discomfort. Used only by iv route. Considerable irritation can occur if extravasated into surrounding tissues. |
| Adverse Effects | Hair loss, leucopenia, neuritic pain, constipation, sensory loss, paraesthesia, difficulty in walking, loss of deep tendon reflexes, muscle wasting, fever, hypersensitivity reaction, weight loss, polyuria, urinary retention, hypertension, cranial nerve palsies, headache, bone pains, parotid pain, myalgia, convulsions, syndrome of inappropriate secretion of ADH. |
| Drug Interactions | If given with phenytoin, there is increased seizure activity. Acute bronchospasm with mitomycin-C. |
| Dosage | Given iv at weekly intervals. Children 2mg/m (if <10kg, start with 0.05mg/kg/week). Adult 1.4 mg/m. Decrease the dose to 50%, if S. bilirubin is >3mg/dl. Not given to patient getting radiation thereby through ports that include liver. |
Product Details:
| Dosage Form | Injection |
| Composition : | 20mg/2 ml, 60mg/1.5ml, 80mg/2ml |
| TOBRAMYCIN: :- | It is an aminoglycoside, highly soluble in water & stable for several week in solutions of various pH. |
| Indications : | Treatment of external infection of the eye and its adnexa caused by susceptible strains of gram-positive, gram-negative & other probable bacteria. Safe & effective in children. |
| Dosage :- | 1-2 drops in the affected eye(s) every 4 hrs. |
| Adult :- | Pneumonias, UTI, skin and skin structure infections: 500 mg 8 hourly. Nosocomial Pneumonias, peritonitis, septicemia: 1gm every 8 hours. |
| Contra-Indications :- | Hypersensitivity |
| Special Precautions : | Not for injection into eye. If sensitivity reaction occurs, discontinue. |
| Paediatrics :- | Safety is not established in patient with neutropenia or primary/secondary immuno-deficiency. Safety is not established in infants under 3 months of age. |
| Pregnancy :- | Safety is not established. |
| Lactation :- | Safety is not established. |
| Elderly :- | Safe for elderly with normal renal functions. |
| Side-effects :- | Localised ocular toxicity and hypersensitivity including itching and swelling and conjuctival erythema |
Product Details:
| Form of Medicine | Injection |
| Usage | Commercial |
| Specification- | pH range- 5.5 to 7.5 Dactinomycin is a clear, gold-colored liquid given into a vein (IV). A compound composed of a two cyclic peptides attached to a phenoxazine that is derived from streptomyces parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also declines after dactinomycin therapy. |
| Indication | For treatment of Wilms' tumor, childhood rhabdomyosarcoma, Ewing's sarcoma and metastatic, nonseminomatous testicular cancer as part of a combination chemotherapy and/or multi-modality treatment regimen. |
| Dosage - | Dose intensity per 2-week cycle for adults or children should not exceed 15 mcg/kg/day or 400-600 mcg/m/day intravenously for five days. |
| Contra Indications- | Active infection with chiken pox or herpes zoster (a severe generalized form of disease may occure), infants less than12 months. |
| Precautions- | This drug is not recommended for use during pregnancy. Precaution is advised when using this drug in the elderly because they may be more sensitive to the effects of the drug, especially the effect on blood cell production (myelosuppression). |
| Drug interaction | Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. |
| Adverse effects | Nausea, vomiting, malaise, fatigue, cheilitis, dysphagia, bone marrow depression gastric ulceration, hepatitis, hepatomegaly, abnormal liver function, alopecia, skin eruotion. |
| Storage | Powder for injection at room temperature (59 Degree to 86 DegreeF). Protect from light and humidity. |
Product Details:
| Product Type | Finished Product |
| Form of Medicine | Injection |
| Usage | Commercial |
| Composition | 2mg, 10mg & 40mg |
| Indications | Disseminated adenocarcinoma of stomach and pancreas. |
| Contraindications | Patients with previous idiosyncratic reaction to the drug, patient with thrombocytopenia, coagulation disorders, increase in bleeding tendency, pregnancy etc. |
| Adverse Effects | Fever, anorexia, nausea, vomiting, bone marrow, depression (within 8 weeks of onset of therapy) etc. Cellulitis at injection site, stomatitis, alopecia, renal impairment, pulmonary toxicity, haemolytic uraemia syndrome (micro angiopathic haemolytic anaemia, thrombocytopenia, irreversible, renal failure), congestive heart failure, headache, visual blurring, diarrhoea, pain etc. |
| Drug Interactions | Potentiates adriamycin induced cardiotoxicity. Synergestic with 5-flurouracil. |
| Dosage | 20 mg/m i.v. single dose via 1/2 catheter. Patient should be fully evaluated after each course and dose decrease if toxicity appears. |
Product Details:
| Product Type | Finished Product |
| Medicine Type | Allopathic |
| Usage | Commercial |
| Composition : | 50mcg/ml, 100mcg/ml |
| Indication : | Insulinomas, zollinger Ellison syndrome, acromegaly, vasoactive intestinal peptide tumours. |
| Contraindications :- | Hypersensitivity. |
| Safety Profile :- | In pregnancy or nursing mothers, it may be used if potential benefits overcome potential risks. |
| Adverse Effects :- | Anorexia, GIT upsets, bloating, pain at inj. Site, pancreatitis. |
| Drug Interactions : | Cimetidine, cyclosporine, cyanocobalamin, insulin. |
| Dosage :- | Initially 0.05 to 0.1mg S.C. every 8-12 hrs max. 1.5 mg daily. |
Product Details:
| Product Type | Finished Product |
| Medicine Type | Allopathic |
| Usage | Commercial |
| Composition : | 250mg,500mg,1gm,2 gm |
Product Details:
| Product Type | Finished Product |
| Medicine Type | Allopathic |
| Usage | Commercial |
| Composition : | 60mg |
| Artesunate: | Artemisinin derivatives are the potent and rapidly acting blood schizonticides. These are cconcentrated in parasitized erythrocytes. Artesunate acts rapidly, stopping parasite development and preventing subsequent cytoadherence and resetting.Artesunate is well distributed and achieves high concentration in the intestines, liver and kidneys. Only a small amount of artesunate is excreted in the urine and in the stools. |
| Indications: | Severe malaria including cerebral malaria and as a second line treatment in chloroquineresistant falciparum malaria. |
| Dosage : Adults : Parenteral: | 120gm on the first day followed by 60mg can be given on the first day itself 6 hours after the first dose. |
| Oral: | 100mg twice a day on the first day followed by 50mg twice daily for the next four days. |
| Children: | 1.2mg/kg x 5 days (maximum 60mg) |
| Contraindications: | Not known |
| Special Precaution: | Avoid in pregnant woman, especially in the first trimester. |
| Paediatrics: | May be used if chloroquine resistant. |
| Pregnancy: | Cpmtraomdocated on 1st trimester. |
| Lactation: | Safety not established. |
| Side-Effects: | Transient and reversible reticulocytopenia, drug fever, drug rash, bradycardia, transient first degree heart block and transient & revesible elevation of serum transaminases. |
| Lactation: | Safety not established. |
| Drug Interactions: | Antimalarial action potentiated by oxidant drugs. Additive effect seen with chloroquine. Antagonistic effect seen with pyrinethamine and sulfonamides. |
| Purity : | Not less than 99%. |
Product Details:
| Product Type | Finished Product |
| Medicine Type | Allopathic |
| Usage/Application | Commercial |
Product Details:
| Type | Allopathic |
| Form of Medicine | Injection |
| Composition : | Each vial contains: Irinotecan 40mg/2ml, 100mg/5ml Water for Injection q.s. |
| Indications : | It is indicated as a component of first-line therapy in combination and leucovorin for patients with metastatic carcinoma of the colon or rectum. It is also indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy. . |
| Contraindications : | It is contraindicated in patients with a known hypersensitivity to the drug or its excipients. |
| Pharmacological action: | Irinotecan is a derivative of camptothecin. It interact specifically with the enzyme topoisomerase I which relieves torsional strain in DNA by inducing reversible single-strand breaks. Irinotecan and its active metabolite SN-38 bind to the topoisomerase I-DNA complex and prevent religation of these single-strand breaks. |
| Adverse Effects : | : Abdominal discomfort, diarrhoea, Leukopenia, neutropenia, haemorrhage, body pain, insomania, dizziness, anaemia vomiting, nausea |
| Dosage : | Irinotecam should be administered as an intravenous infusion over 90 minutes for both the weekly and once-every-3-week dosage schedules. Weekly dose schedule: The usual starting dose is 125 mg/m2. Subsequent doses may be adjusted to as high as 150 mg/m2. Once every three week schedule: starting dose is 350 mg.m2 |
| Storage: | 2-80C |
Product Details:
| Type | Allopathic |
| Form of Medicine | Injection |
| Usage | Commercial |
| Specification- | Light Greenish color powder filled in glass vials. pH 2.5 to 4.5 |
| Indication : | Metastatic carcinoma of the ovary after failure of initial or subsequent chemo therapy. Small cell lung cancer disease after failure of first line chemotherapy |
| Dosage :- | Recommended starting dose is 1.5mg/m2 body surface area by IV infusion over 30 minutes daily for 5 consecutive days In absence of tumor progression, a minimum of four courses are recommended, as tumour response may be delayed. |
| Contraindications:- | Severe hypersensitivity reactions (e.g., anaphylactoid reactions) Pregnant or Breastfeeding, Severe bone marrow depression. |
| Precautions:- | Bone Marrow Suppression, Thrombocytopenia, Diarrhea, Interstitial Lung Disease, Pregnancy Neutropenia, Thrombocytopenia, Anemia. |
| Drug interaction: | Cyclosporine A (inhibitor of ABCB1, ABCC1 [MRP-1], and CYP3A4) with hycamtin capsules increased topotecan exposure to 2- to 3-fold of control. The pharmacokinetics of topotecan were generally unchanged when coadministered. |
| Adverse Effect-: | Bone marrow suppression. Primarily neutropenia, thrombocytopenic anaemia, abdominal discomfort. |
| Storage: | Store between 2-80C |
| Amiloride Hydrochlorothiazide | 5mg 50mg |
| Amiodarone | 100mg, 200mg |
| Amlodipine | 2.5mg, 5mg, 10mg |
| Amlodipine Atenolol | 5mg 50mg, 5mg 25mg |
| Amlodipine Enalapril | 5mg 5mg |
| Atenolol | 50mg, 100mg |
| Atenolol Nifedipine | 50mg 20mg |
| Atorvastatin | 10mg, 20mg |
| Chlorthalidone | 100mg |
| Clonidine | 100mcg, 150mcg |
| Labetalole | 100mg |
| Losartan Potassium | 25mg, 50mg |
| Losartan Potassium Amlodipine | 50mg 5mg, 25mg 5mg |
| Losartan Potassium Hydrochlorothiazide | 50mg 12.5mg |
| Nebivolol S-Amlodipine Besylate | 5mg 2.5mg |
| Nifedipine | 10mg, 20mg |
| Olmesartan Amlodipine | 20mg 5mg |
| Prazosin | 2.5mg |
| Propranolol | 10mg, 40mg, 80mg |
| Quinidine | 200mg, 300mg |
| Ramipril | 2.5mg, 5mg |
| Ramipril Hydrochlorothiazide | 2.5mg 12.5mg, 5mg 12.5mg |
| Reserpine | 0.25mg |
| Telmisartan | 20mg, 40mg |
| Telmisartan Hydrochlorothiazide | 40mg 12.5mg |
| Verapamil | 40mg, 80mg |
Product Details:
| Type | Allopathic |
| Usage | Commercial |
| Form of Medicine | Injection |
| Specification- | pH range – : 5.5 to 6.5 Leuprolide acetate is a synthetic nonapeptide analog of naturally occurring gonadotropin releasing hormone (GnRH or LH-RH). The analog possesses greater potency than the natural hormone. It is a sterile, aqueous solution intended for subcutaneous injection. |
| Indication : | Advanced prostatic carcinoma when orchidectomy or oestrogen administration is not indicated. |
| Dosage :- | SC inj., 1 mg single dose. |
| Contraindications:- | Pregnancy, in women who may become pregnant while receiving the drug, and during lactation. Sensitivity to benzyl alcohol (found in leuprolide injection). Undiagnosed abnormal vaginal bleeding. Hypersensitivity to GnRH/GnRH agonist analogs. The 30-mg depot in women. |
| Precautions:- | Patients with metastatic vertebral lesions and/or with urinary tract obstruction should be closely observed during the first few weeks of therapy. Patients with known allergies to benzyl alcohol, an ingredient of the drug's vehicle, may present symptoms of hypersensitivity, usually local, in the form of erythema and induration at the injection site. |
| Drug interaction: | Administration of leuprolide acetate in therapeutic doses results in suppression of the pituitary-gonadal system. Normal function is usually restored within 4 to 12 weeks after treatment is discontinued. Administration of leuprolide acetate in therapeutic doses results in suppression of the pituitary-gonadal system. Normal function is usually restored within 4 to 12 weeks after treatment is discontinued. |
| Adverse Effect-: | High blood pressure, ischemia, insomnia, constipation, urinating more often than usual, bone pain, loss of movement in any part of your body; swelling, rapid weight gain. |
| Storage: | : Store unopened bottles in the refrigerator. Vials can be kept at room temperature (less than 86 degrees F or 30 degrees C). Do not freeze. Protect from light. |
Product Details:
| Form of Medicine | Injection |
| Usage | Commercial |
| Indication : | Dacarbazine for injection is indicated in the treatment of metastatic malignant melanoma. In addition, dacarbazine for injection is also indicated for Hodgkin's disease as a secondary-line therapy when used in combination with other effective agents. |
| Dosage :- | Malignant melanoma : 2-4.5 mg/kg/day for 10 days may be repeated at 4 weeks intervel or 250 mg/ml of body surface area (BSA)/day for 5 days repeated after 3 weeks. Hodgkin's disease : 150mg/m² to be repeated every 15 days. |
| Contra Indications:- | Dacarbazine for injection is contraindicated in patients who have demonstrated a hypersensitivity to it in the past. |
| Precautions:- | Breast-feeding is usually stopped while using anticancer drugs. Dacarbazine should be used only when clearly needed during pregnancy. |
| Drug interaction: | Impairs immune response to vaccines; possible infection after admin of live vaccines. Effect increased by CYP1A2 inhibitors e.g. amiodarone, ciprofloxacin, fluvoxamine, ketoconazole, lomefloxacin, ofloxacin. Effect decreased by CYP1A2 inducers e.g. aminoglutethimide, carbamazepine, phenobarbital and rifampicin. |
| Adverse effects: | Haemopoietic depression invading mainly leucocytes and platelets anaphylactoid reaction, anorexia, nausea, vomiting, diarrhoea, influneza like syndrome, alopecia, facial flushing, paresthesia, ash liver function and renal function abnormalities |
| Storage: | Store in a refrigerator 2°C to 8°C (36°F to 46°F). dacarbazine Use within 8 hours of reconstitution. Protect from light |
Product Details:
| Product Type | Finished Product |
| Form of Medicine | Injection |
| Usage | Commercial |
| Composition : | 20mg |
| Indications : | Remission indication in non lymphocytic leukemia, acute erythroid, leukemia, acute monocytic, leukemia, acute myelogenous leukemia, acute Lymphoblast |
| Contraindications : | Pre- existing drug induced bone marrow supression, pre-existing heart disease, pregnancy. |
| Safety Profile : | Cardiac, renal & hepatic functions adn serum uric levels should be evaluated prior to treatment. Completed blood count should be frequently monitored during the therapy extravasation at site of injections may causes severe local tissue necrosis. |
| Adverse Effects : | Myelosuppression, myocardial toxicity, infants and children's are more susceptible to congestive heart failure (CHF), reversible alopecia gastrointestinal A special preparation as daunorubicin citrate liposome contain an equal amount of citrate encapsulated in lipid vesicles, formulated to maximize the selectivity of the drug for soiled tumors in sites. |
| Drug Interactions : | 1st line drug for advanced HIV associated keposi's saecoma. |
| Dosage : | Acute nonlymphocytic leukemia: Less than 60 years age -45 mg/m²/day i.v on days 1,2,3 on first course and on day 1&;2 on subsequent course with cytosine. Acute Lymphocytic leukemia (All): Chlidren 25 mh/ m² i.v on day every week with prednisolone and vincristine.In < 2yrs of age: mg/kg dose in same manner Adult: 45 mg/m²per day i.v on drug 1,2,3 with vincristine., prednisolone and L-asparaginase. In < 2yrs of age: mg/kg dose in same manner Adult: 45 mg/m²per day i.v on drug 1,2,3 with vincristine., prednisolone and L-asparaginase. |
| Piroxicam: | Its anti- inflammatory potency is similar to indomethacin and analgesic action is greater than aspirin. It has useful antipyretic proerty. |
| Indications: | Its anti- inflammatory potency is similar to indomethacin and analgesic action is greater than aspirin. It has useful antipyretic proerty. |
| Dosage: | Rheumatod arthritis, osteroarthritis, ankylosing, Spondylitis: 20mg daily as single dose. Maint : 10-30 mg .Acute Musculo-skeletal disorders: 40mg in a single or divided doses for 7-14 days. Acute gout : 40 mg as a single dose. Maint : 40 mg in single or divided doses for 4-6 days. |
| Contra-Indications: | Hypersensitivity , pregnancy children patients who develop asthama or allergy with other inflammatory drugs, lactation. |
| Special Precautions: | Renal or hepatic dysfunction, asthma surgery, haemorrhagic disorders. Hypertension. Cardiovascular disease. |
| Paediatrics: | Not recommended in age below 6 yrs. |
| Pregnancy: | Contraindicated may affect the foetus. |
| Lactation: | Safety not established. |
| Elderly: | Reduced dose necessary. |
| Side Effects: | Heart burn, nausea, anorexia, rashes, pruritus, C.N.S. manifestations. Oedema. |
| Drug Interactions: | Potentiate anticoagulants. Diuretics increase risk of renal damage. Monitor lithium levels. Aspirin reduces serum levels. |
| Purity : | Not less than 99%. |
Product Details:
| Form | Injection |
| Specification- | pH: 6.0 7.1 |
| Indication : | Fludarabine is primarily indicated in conditions like Chronic lymphocytic leukaemia,Lymphoid malgnancies, and can also be given in adjunctive therapy as an alternative drug of choice in Acute leukemia, Indolent lymphoma, Myclodysplastic syndrome, Myelodysplastic syndrome, Myeloid leukaemia. |
| Dosage :- | The recommended adult dose of fludarabine for injection is 25 mg/m² administered intravenously over a period of approximately 30 minutes daily for five consecutive days. Each 5 day course of treatment should commence every 28 days. |
| Contra Indications:- | Fludarabine is contraindicated in conditions like Peripheral neuropathy, HIV infection, Renal impairment, Central neuropathy. |
| Precautions:- | During/after treatment with fludarabine for injection, vaccination with live vaccines should be avoided. If it is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus. Women of childbearing potential should be advised to avoid becoming pregnant. |
| Drug interaction: | The use of Fludarabin for injection in combination with pentostatin is not recommended due to the risk of severe pulmonary toxicity. |
Product Details:
| Product Type | Finished Product |
| Medicine Type | Allopathic |
| Usage/Application | Commercial |
| Composition : | 1mg/2ml, 15mg/30ml |
| Indications : | Pain, Fever. |
| Contraindications: | Hypersensitivity,hepatic porphyria,Collapse states, infants less than 3 month of age or 5kg body wt. |
| Safety Profile : | Disorders of haematopoiesis. |
| Adverse Effects : | Hypersensitivity,bronchial tract, gastric symptoms. |
| Drug Interactions | Cyclosporine level increased. |
| Dosage : | Adults : Oral ; 0.5-1.5gm in 2-3divided doses. Parenteral : 2ml IM. 2-3 times daily.Children : Oral 30-60 mg/kg/day Parenteral (All four times/day by slow IV) : 3 month to 1 year : 0.1ml, below 5 years : 0.2ml, 5-7 years : 0.4ml, 8-11 years : 0.5ml, 12-14 years : 0.8ml |
| Purity : | Not less than 99%. |
Product Details:
| Product Type | Finished Product |
| Usage/Application | Commercial |
| Specification- | pH: 6.0 7.1 |
| Indication : | Fludarabine is primarily indicated in conditions like Chronic lymphocytic leukaemia,Lymphoid malgnancies, and can also be given in adjunctive therapy as an alternative drug of choice in Acute leukemia, Indolent lymphoma, Myclodysplastic syndrome, Myelodysplastic syndrome, Myeloid leukaemia. |
| Dosage :- | The recommended adult dose of fludarabine for injection is 25 mg/m² administered intravenously over period of approximately 30 minutes daily for five consecutive days. Each 5 day course of treatment should commence every 28 days. |
| Contra Indications:- | Fludarabine is contraindicated in conditions like Peripheral neuropathy, HIV infection, Renal impairment, Central neuropathy. |
| Precautions:- | During and after treatment with fludarabine for injection, vaccination with live vaccines should be avoided. If it is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus. Women of childbearing potential should be advised to avoid becoming pregnant. |
| Drug interaction: | The use of Fludarabin for injection in combination with pentostatin is not recommended due to the risk of severe pulmonary toxicity. |
| Storage: | Store in refrigerator. Use within 8 hrs if kept at room temperature. |
Product Details:
| Dosage Form | Injection |
| Composition : | 150mg/2ml |
| Indications : | Chloroquine resistant malaria, complicated falciparam malaria and cerebral malaria . |
| Purity : | Not less than 99%. |
Product Details:
| Product Type | Finished Product |
| Medicine Type | Allopathic |
| Usage/Application | Commercial |
| Composition : | 80mg/1ml |
| Indications : | Chloroquine sensitive, chloroquine resistant and multidrug resistant falciparum malaria & severe malaria including cerebral malaria. |
| Contraindications : | Patient with cardiac problems and pregnancy for longer use. |
| Safety Profile : | Drugs known to produce heart block or prolong QT interval should be avoided while artemether is being administer. 1st trimester of pregnancy is contraindication for its use. |
| Adverse Effects : | Nausea, vomiting, abdominal pain, bradycardia, first degree heart block, transient increase in transaminases, reversible decrease in reticulocyte count. |
| Dosage : | A 5-day dose scheme is followed 80mg .m. Twice a day on day one, followed by 80mg i.m. Once a day for follow. |
| Purity : | Not less than 99%. |
Product Details:
| Product Type | Finished Product |
| Usage/Application | Commercial |
| Composition : | 6mg/2ml, 30mg/10ml |
| Indications : | Treatment of PSVT. Diagnosis ofre-entrant atrial and ventricular tachycardia. |
| Contraindications : | Various degrees of heart block, sicksinus syndrome and bronchial asthma . |
| Safety Profile : | In patients of atrialflutter/fibrillation, in pregnancy used if absolute necessary. |
| Adverse Effects : | Flushing, dyspnoea, nausea, lightheadedness, sweating, palpitation & heaviness in arms. |
| Dosage : | Adults - initial dose of 3.5mg asrapid intravenous bolus, second dose is repeated after 2 mts, if firstdose fails to abort the attack of PSVT. It is given 6mg rapidlyintravenously, If attack still persists, give third dose of 12mg rapidlyintravenously. Additional or higher doses are not recommended. |
| Purity : | Not less than 99%. |
Product Details:
| Type | Allopathic |
| Form of Medicine | Injection |
| Usage | Commercial |
| Pharmacological Action : | Bleomycin is a mixture of cytotoxic glycopeptide antibiotics. It inhibits DNA synthesis. When administered intrapleurally, bleomycin acts as a sclerosing agent. |
| Precautions: | Bleomycin be administered under the supervision of a qualified health care provider experienced in the use of cancer chemotherapeutic agents. Appropriate management of therapy and complications is possible only when adequate diagnostic and treatment facilities are readily available. Before using Bleomycin Sulfate for injection medication, tell your doctor or pharmacist your medical history, especially: immune system problems (e.g., chemotherapy, bone marrow problems), kidney disease, liver disease, lung problems. |
| Indications: | Bleomycin Sulfate Injection should be considered a Palliative Treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: Squamous Cell Carcinoma in Head and neck including mouth, tongue, tonsil, Nasopharynx, Oropharynx, Sinus, palate, Lip, Buccal Mucosa, Gingivae , Epiglottis, skin, Larynx, Cervix, and Vulva. Lymphomas, Testicular Carcinoma, Malignant Pleural Effusion. |
| Contraindications : | Bleomycin Sulfate injection is contraindicated in patients who have demonstrated a hypersensitive or an idiosyncratic reaction to it. |
| Adverse Effects : | Pneumonitis progressing to pulmonary anaphylactoid reactions, erythema, rash, striae, vesiculation, hyperpigmentation, rarely myocardial infarction, cerebrovascular accident, haemolytic uraemia syndrome, cerebral arthritis. Local reactions : Pain, pruritus, hyperpigmentation, scarring, suppuration scaling. |
| Dosage : | Bleomycin Sulfate injection may be given by the Intramuscular, intravenous, subcutaneous, or Intrapleural routes. Squamous cell carcinoma, non-Hodgkin's lymphoma, testicular carcinoma- 0.25 to 0.50 units/kg (10 to 20 units/m�) given intravenously, intramuscularly, or subcutaneously weekly or twice weekly. Hodgkin's disease:- 0.25 to 0.50 units/kg (10 to 20 units/m�) given intravenously, intramuscularly, or subcutaneously weekly or twice weekly. Note: When Bleomycin sulfate injection is used in combination with other antineoplastic agents, pulmonary toxicities may occur at lower doses. Malignant Pleural Effusion - 60 units administered as a single dose Bolus Intrapleural Injection. Intramuscular or Subcutaneous: Bleomycin Sulfate injection 15 units vial should be reconstituted with 1 to 5 ml of Sterile Water for Injection, Sodium Chloride for Injection 0.9% or Sterile Bacteriostatic Water for Injection. Bleomycin Sulfate injection 30 units vial should be reconstituted with 2 to 10 ml of the above diluents. Intravenous: The contents of the 15 units or 30 units vial should be dissolved in 5 ml or 10 ml, respectively, of Sodium Chloride for Injection, 0.9% and administered slowly over a period of 10 minutes. |
Product Details:
| Dosage Form | Injection |
Product Details:
| Product Type | Finished Product |
| Usage | Commercial, Clinical, Hospital |
Product Details:
| Prescription/Non prescription | Prescription |
| Usage/Application | Commercial |
| Medicine Type | Injection |
Product Details:
| Usage | Hospital |
| Product Type | Finished Product |
| Usage/Application | Commercial |
Product Details:
| Product Type | Finished Product |
| Usage/Application | Commercial |
Product Details:
| Product Type | Finished Product |
| Injectable Form | Injection |
| Usage/Application | Commercial |
Product Details:
| Injectable Form | Injection |
| Medicine Type | Allopathic |
Meropenem / Sulbactam is used for Bacterial infections, Lung infections, Bronchial infections, Infections during delivery, Infections after delivery, Management of reduced white blood cells patients with fever, Bacterial blood poisoning, Intraabdominal infections, Gynecological infections, Skin or soft tissue infections and other conditions.
Meropenem Sulbactam 1.5gm Injection